ImmuCell Corporation (ICCC)
$9.80+0.51%Close
SELLBEAR · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $89M
- Beta
- 0.57
- P/E (TTM)
- 117.85
- Short % float
- 0.37%
- Days to cover
- 1.8
- SI change
- +11.5%
- 1W
- +0.51%
- 1M
- -1.11%
- vs SPY 1W
- -0.65%
- vs SPY 1M
- -4.10%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 5
- GROWTH
- 57
- GARP
- 8
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC1.6%
REV YoY-
ROE2.7%
EPS YoY-
ROA1.7%
GROSS40
OP13
NET3
[VALUATION]
P/E TTM117.85
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B2.88
P/FCF-
EV/EBITDA26.52
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E39.67
ALTMAN Z-
CURR RATIO4.75
ND/EBITDA-
BETA0.57
Company news
FAQ
- What is LOPJLB’s current signal on ICCC?
- LOPJLB’s latest quantitative signal on ImmuCell Corporation (ICCC) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is ICCC in?
- ImmuCell Corporation (ICCC) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does ImmuCell Corporation (ICCC) do?
- ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy …